JS Link
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
JS Link provides genomic analysis and bioinformatics services, helping decode DNA sequences to support disease prevention, diagnosis, and personalised treatment.
Its services are used in precision medicine, clinical diagnostics, and related healthcare fields, including areas such as beauty, anti-ageing, and wellness. Listed on KOSDAQ, Korea's tech and small-cap board, the company operates across three lines: genomic analysis, personalised medicine, and diagnostic testing.
Summary is AI-generated and may contain errors · figures from DART filings
JS Link in five facts
What does JS Link do?
JS Link provides genomic analysis and bioinformatics services, helping decode DNA sequences to support disease prevention, diagnosis, and personalised treatment.
Where is JS Link listed and in which sector?
JS Link (Korean name: 제이에스링크) trades under KRX code 127120 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is JS Link?
Its market capitalisation was US$536.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were JS Link's latest annual revenue and operating profit?
For fiscal year 2025, JS Link reported revenue of US$14.6M, an operating loss of US$9.4M and a net loss of US$12.4M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was up 21.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 16
- Report on large shareholdings (5% rule) (standard)Oct 12
- Report on large shareholdings (5% rule) (standard)Oct 8
- DisclosureOct 1
- Investor relations (IR) meetingSep 30
- [Amended] Supply contract signed
JS Link updated a previously disclosed supply contract with Korea Research Institute of Bioscience and Biotechnology, now worth US$7.94M, about 48.79% of its recent annual revenue, running through Dec 2026.
Supply contract · Sep 10 - Change of CEOSep 9
- [Amended] Decision to acquire shares/equity in another company
JS Link updated the disclosed terms of an acquisition of JS LINK MAGNETICS MALAYSIA, now worth US$36.6M.
M&A · Aug 31 · 3 versions - Report on securities held by executives/major shareholdersAug 31
- Material event report (decision to redeem own convertible bonds early)
JS Link resolved on August 24, 2026 to redeem US$3.66M in face value of its 14th-series unsecured private convertible bonds before maturity for US$3.86M, by exercising its issuer call option, from bondholders Sangsangin Savings Bank, Sangsangin Plus Savings Bank, and Sangsangin Securities.
Capital raise · Aug 24 - Securities issuance results (voluntary) (third-party placement)
JS Link completed a third-party placement rights offering, issuing 1,668,531 common shares for US$37M, with payment made on 2026-07-29; the new shares are expected to be listed.
Capital raise · Jul 29 - [Amended] Material event report (rights offering)
JS Link updated the terms of a private placement (third-party allotment) to raise US$36.1M, about 4.7% of its market value.
Capital raise · Jul 21 · 3 versions - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$3.23M, about 0.4% of its market value.
Capital raise · Jun 26 - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$3.26M, about 0.4% of its market value.
Capital raise · Jun 23 - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$16.3M, about 2.2% of its market value.
Capital raise · Jun 23 - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$16.4M, about 2.2% of its market value.
Capital raise · Jun 17 - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$3.28M, about 0.4% of its market value.
Capital raise · Jun 17 - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$3.28M, about 0.4% of its market value.
Capital raise · Jun 10 - [Amended] Material event report (convertible bonds)
JS Link updated the terms of convertible bonds to raise US$16.4M, about 2.2% of its market value.
Capital raise · Jun 10 - Supply contract signed
JS Link disclosed a supply contract with Korea Disease Control and Prevention Agency National Institute of Health, worth US$1.67M, about 12.88% of its recent annual revenue, running through Dec 2026.
Supply contract · May 13 - Material event report (convertible bonds)
JS Link disclosed convertible bonds to raise US$3.36M, about 0.4% of its market value.
Capital raise · May 13 - Material event report (convertible bonds)
JS Link disclosed convertible bonds to raise US$16.8M, about 2.2% of its market value.
Capital raise · May 13 - [Amended] Supply contract signed
JS Link updated a previously disclosed supply contract with Korea Research Institute of Bioscience and Biotechnology, now worth US$6.93M, about 47.64% of its recent annual revenue, running through Dec 2026.
Supply contract · Mar 27 - [Amended] Change of 30% or more in revenue or profit/loss structure (15% for large companies)
JS Link updated its previously filed consolidated results for FY2025: revenue of US$13.1M (+21.43% year on year), an operating loss of US$8.49M and a net loss of US$11.2M.
Earnings · Mar 13 · 2 versions - Securities issuance results (voluntary) (third-party placement)Capital raise · Feb 3
- Material event report (CB call option holder designated)Capital raise · Jan 26
- [Amended] Material event report (rights offering)Capital raise · Jan 26